#ESC22: 89bio heads toward PhIII in severe hypertriglyceridemia, a field left behind by Pfizer earlier this year
BARCELONA — Two months after revealing the topline data — and quickly going to the market for a capital infusion of $95 million — 89bio is now presenting the mid-stage results of its high-triglyceride drug at the European Society of Cardiology Congress.
In patients with severe hypertriglyceridemia (SHTG) — in which triglyceride levels are more than three times what they should be and can lead to cardiovascular disease — 89bio’s drug performed better than placebo. The FGF21 analog, named pegozafermin, will enter a Phase III trial in the first half of next year, and data from a Phase IIb in patients with NASH, which recently completed enrollment, is slated for early next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.